We show that spironolactone use was associated with an increased rate of all-cause hospitalizations, but no difference in hospitalizations for heart failure or pulmonary arterial hypertension, in patients with World Health Organization Group 1 pulmonary arterial hypertension. A possible reason for this finding is confounding from retrospective study design.
Results of Mitral Valve Surgery with Pulmonary Arterial Hypertension: Analysis of a Retrospective Study
